NMIBC recurrent transurethral Laser Ablation

NMIBC chemotherapy intravesical

NMIBC chemotherapy hyperthermia

Humans *Adjuvants Immunologic/therapeutic use/adverse effects Administration Intravesical Neoplasm Recurrence Local/epidemiology *Urinary Bladder Neoplasms/pathology Drug Administration Schedule Bcg Cvnmi Desabastecimiento Dosis completa Dosis reducida Full dose Nmibc Reduced dose Shortage

Humans Mitomycin/therapeutic use Antibiotics Antineoplastic BCG Vaccine/therapeutic use *Non-Muscle Invasive Bladder Neoplasms Neoplasm Recurrence Local/drug therapy *Urinary Bladder Neoplasms/pathology Administration Intravesical Neoplasm Invasiveness Bladder cancer Device-assisted Emda Intravesical drug administration Nmibc

Cisplatin/adverse effects Humans *Immunotherapy/adverse effects/methods *Muscles/pathology *Neoadjuvant Therapy/adverse effects Neoplasm Staging *Urinary Bladder Neoplasms/drug therapy/pathology/therapy chemoimmunotherapy immunotherapy meta-analysis muscle-invasive bladder cancer (MIBC) neoadjuvant commercial or financial relationships that could be construed as a potential conflict of interest.

Bcg Bacillus Calmette–Guérin Nmibc bladder cancer checkpoint inhibition therapy nadofaragene firadenovec non muscle invasive oncolytic viruses

Radical cystectomy bladder preservation distant metastasis rate (DMR) muscular invasive bladder cancer (MIBC) survival rate form (available at https://dx.doi.org/10.21037/tau-21-564). The authors have no conflicts of interest to declare.

*Cystoscopy Follow-Up Studies Humans Neoplasm Invasiveness Neoplasm Recurrence Local Prospective Studies *Urinary Bladder Neoplasms/diagnosis/therapy Nmibc Non-muscle invasive bladder cancer cystoscopy follow-up

Quality of life (QoL) bladder cancer non-muscle invasive bladder cancer (NMIBC) surveillance form (available at http://dx.doi.org/10.21037/tau-20-1333). The series “Expectant Management in Genitourinary Malignancies (Prostate Bladder Kidney)” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Adjuvants Immunologic/adverse effects Administration Intravesical BCG Vaccine/adverse effects Humans *Urinary Bladder Neoplasms/drug therapy *Urology Antibiothérapie Antibiotic therapy BCG therapy BCG thérapie Bladder Carcinome urothélial Complications Endovesical instillations Instillations endovésicales Nmibc Tvnim Urothelial carcinoma Vessie

Administration Intravesical Drug Therapy/instrumentation Humans Neoplasm Invasiveness Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/pathology Emda Nmibc NMIBC Carcinome de la vessie TURBT EMDA RITE Synergo Rite Synergo Turbt Urothelial carcinoma

Css Os Pfs neoadjuvant chemotherapy outcome primary MIBC secondary MIBC

非肌层浸润性膀胱癌(NMIBC) 羟喜树碱 吉西他滨 表柔比星 Meta分析

Bacille Calmette-Guérin Nmibc gemcitabine intravesical therapy meta-analysis non-muscle invasive bladder cancer

Cation Transport Proteins/*genetics Glutathione Peroxidase/*genetics Humans Neoplasm Recurrence Local/genetics Polymorphism Genetic Survival Analysis Urinary Bladder Neoplasms/genetics/*pathology Glutathione Peroxidase GPX1 Nmibc Nramp1 d534n hGPX1 Pro168Leu meta-analysis recurrence

Age Factors Aged Aged 80 and over Clinical Decision-Making *Cystectomy/adverse effects/mortality Disease-Free Survival Female Geriatric Assessment Humans Life Expectancy Male Middle Aged Neoplasm Invasiveness Odds Ratio Patient Selection Quality of Life Radiotherapy/adverse effects/mortality Risk Factors Time Factors Treatment Outcome Urinary Bladder Neoplasms/mortality/pathology/*therapy Complications Elderly Mibc Outcome